Oryzon Genomics, S.A., presented yesterday positive preclinical efficacy data of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor
Read moreThe CaixaResearch Artificial Placenta project, led by BCNatal (Hospital Clínic Barcelona - SJD Barcelona Children's Hospital), is the first experimental project on artificial placenta with animal mod...
Read moreLa prestigiosa revista americana Gastrointestinal Endoscopy acaba de publicar un estudio multicéntrico sobre terapéutica de tumores subepiteliales gastrointestinales, liderado por la Unidad de Endos...
Read moreHan demostrado en un estudio como el gen MAPK11 es clave para entender los fenómenos de radio resistencia en las células tumorales al controlar el proceso de senescencia, una de las respuestas clave...
Read moreEl sistema inmunitario se encarga de mantener los microbios patógenos a raya desplegando múltiples mecanismos. Cuando las células inmunes encuentran potenciales patógenos, se activan cascadas de s...
Read moreUna nueva técnica de reproducción asistida que activa los espermatozoides ha finalizado con éxito su primer ensayo clínico con el nacimiento de un bebé, de padres con un largo historial de i...
Read moreCorWave raised 61 million euros to fund its first industrial deployment and entry into clinical trials. SPI fund, managed by Bpifrance on behalf of the French Government as part of France 2030, and le...
Read moreA study proposed an exhaustive study of the small RNA levels in the extracellular vesicles of the semen of azoospermic individuals. The objective was to select non-invasive biomarkers with diagnostic ...
Read moreThe study, published in the journal Nature Communications, opens the door to the development of effective drug candidates that fully harness the therapeutic potential of Siglec-15. This knowledge will...
Read moreResearchers of the University of Barcelona and the Institute of Bioengineering of Catalonia (IBEC) have identified new biomarkers for non-small cell lung cancer, the most common l...
Read moreThe phase III randomized multi-center CAPItello-291 assessed the efficacy and safety of novel AKT inhibitor capivasertib plus fulvestrant in patients with advanced HR+/ HER2- breast cancer who had pro...
Read moreDeveloped by CNIO and the University of Vigo, the PanDrugs2 programme analyses alterations in tumour genes, relates them to existing available drugs, and reports on the most suitable ones
Read more